Logo image of TRVI

TREVI THERAPEUTICS INC (TRVI) Stock Fundamental Analysis

NASDAQ:TRVI - US89532M1018 - Common Stock

7.255 USD
+0.04 (+0.62%)
Last: 8/29/2025, 8:00:01 PM
7.25 USD
0 (-0.07%)
After Hours: 8/29/2025, 8:00:01 PM
Fundamental Rating

3

Overall TRVI gets a fundamental rating of 3 out of 10. We evaluated TRVI against 195 industry peers in the Pharmaceuticals industry. TRVI has a great financial health rating, but its profitability evaluates not so good. TRVI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TRVI has reported negative net income.
TRVI had a negative operating cash flow in the past year.
TRVI had negative earnings in each of the past 5 years.
In the past 5 years TRVI always reported negative operating cash flow.
TRVI Yearly Net Income VS EBIT VS OCF VS FCFTRVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

TRVI has a Return On Assets (-22.70%) which is in line with its industry peers.
The Return On Equity of TRVI (-23.83%) is better than 64.62% of its industry peers.
Industry RankSector Rank
ROA -22.7%
ROE -23.83%
ROIC N/A
ROA(3y)-33.14%
ROA(5y)-51.42%
ROE(3y)-36.8%
ROE(5y)-85.78%
ROIC(3y)N/A
ROIC(5y)N/A
TRVI Yearly ROA, ROE, ROICTRVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TRVI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRVI Yearly Profit, Operating, Gross MarginsTRVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

TRVI has more shares outstanding than it did 1 year ago.
TRVI has more shares outstanding than it did 5 years ago.
TRVI has a better debt/assets ratio than last year.
TRVI Yearly Shares OutstandingTRVI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TRVI Yearly Total Debt VS Total AssetsTRVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

TRVI has an Altman-Z score of 52.08. This indicates that TRVI is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 52.08, TRVI belongs to the best of the industry, outperforming 98.97% of the companies in the same industry.
There is no outstanding debt for TRVI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 52.08
ROIC/WACCN/A
WACCN/A
TRVI Yearly LT Debt VS Equity VS FCFTRVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

TRVI has a Current Ratio of 22.42. This indicates that TRVI is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 22.42, TRVI belongs to the best of the industry, outperforming 92.82% of the companies in the same industry.
TRVI has a Quick Ratio of 22.42. This indicates that TRVI is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 22.42, TRVI belongs to the best of the industry, outperforming 92.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 22.42
Quick Ratio 22.42
TRVI Yearly Current Assets VS Current LiabilitesTRVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for TRVI have decreased by -7.69% in the last year.
EPS 1Y (TTM)-7.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.50% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y14.93%
EPS Next 2Y-4.58%
EPS Next 3Y-12.53%
EPS Next 5Y8.5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRVI Yearly Revenue VS EstimatesTRVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 500M 1B
TRVI Yearly EPS VS EstimatesTRVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TRVI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRVI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRVI Price Earnings VS Forward Price EarningsTRVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRVI Per share dataTRVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

A cheap valuation may be justified as TRVI's earnings are expected to decrease with -12.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.58%
EPS Next 3Y-12.53%

More info and screens

0

5. Dividend

5.1 Amount

TRVI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TREVI THERAPEUTICS INC

NASDAQ:TRVI (8/29/2025, 8:00:01 PM)

After market: 7.25 0 (-0.07%)

7.255

+0.04 (+0.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-04 2025-11-04
Inst Owners69.61%
Inst Owner Change28.56%
Ins Owners0.83%
Ins Owner Change0.21%
Market Cap883.51M
Analysts86.25
Price Target21.01 (189.59%)
Short Float %9.68%
Short Ratio5.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.89%
Min EPS beat(2)12.64%
Max EPS beat(2)27.14%
EPS beat(4)3
Avg EPS beat(4)10.37%
Min EPS beat(4)-7.61%
Max EPS beat(4)27.14%
EPS beat(8)5
Avg EPS beat(8)4.6%
EPS beat(12)9
Avg EPS beat(12)11.06%
EPS beat(16)13
Avg EPS beat(16)12.49%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.63%
PT rev (3m)3.87%
EPS NQ rev (1m)6.5%
EPS NQ rev (3m)27.27%
EPS NY rev (1m)7.11%
EPS NY rev (3m)9.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.45
P/tB 4.45
EV/EBITDA N/A
EPS(TTM)-0.42
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0
BVpS1.63
TBVpS1.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.7%
ROE -23.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.14%
ROA(5y)-51.42%
ROE(3y)-36.8%
ROE(5y)-85.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.29%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.42
Quick Ratio 22.42
Altman-Z 52.08
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)178.4%
Cap/Depr(5y)119.04%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y14.93%
EPS Next 2Y-4.58%
EPS Next 3Y-12.53%
EPS Next 5Y8.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.37%
EBIT Next 3Y-14.39%
EBIT Next 5Y-21.48%
FCF growth 1Y-28.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.88%
OCF growth 3YN/A
OCF growth 5YN/A